A

Agenus

D
AGEN
USD
-0.07
(-1.1551%)
Market Closed
8,235.00
Volume
-8.34
EPS
-
Div Yield
-0.537702
P/E
129,215,926.59
Market Cap
Today
-1.1551%
1 Week
1.012%
1 Month
17.682%
6 Months
-46.784%
12 Months
-75.847%
Year To Date
-63.872%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ADMP
(%)
USD
A
ALNY
3.06
(1.1203%)
USD
AMGN
AMGN
3.02
(0.9071%)
USD
A
ARWR
0.35
(1.6851%)
USD
F
FATE
0.12
(3.0928%)
USD
GILD
GILD
0.015
(0.0179%)
USD
I
IMGN
(%)
USD
I
INCY
1.67
(2.5625%)
USD
J
JAZZ
1.66
(1.5152%)
USD

Title:
Agenus

Sector:
Healthcare
Industry:
Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Do you need help or have a question?
Contact Us